Immunobiology of β-cell destruction

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 194-218

  La Torre, Daria ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DEATH; CELL DESTRUCTION; DENDRITIC CELL; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; HEREDITY; HLA GENE; HUMAN; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTE HOMING; NATURAL KILLER T CELL; NONHUMAN; PANCREAS ISLET BETA CELL; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOLOGY; PATHOLOGY; REVIEW;

DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE SYSTEM; INSULIN-SECRETING CELLS;

MLCS; MLOWN;

EID: 84874538072     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_16     Document Type: Article

References (221)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229.
2. Committee AE. Report of the expert committee on the diagnosis and Classification of diabetes mellitus. Diabetes Care 1997; 20:1183-1197.
3. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation and management. Pediatr Clin North Am 2005; 52:1553-1578.
4. Onkamo P, Vaananen S, Karvonen M et al. Worldwide increase in incidence of Type I diabetes-the analysis of the data on published incidence trends. Diabetologia 1999; 42:1395-1403.
5. Patterson CC, Dahlquist GG, Gyurus E et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027-2033.
6. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ 1995; 311:913-917.
7. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360:1646-1654.
8. Marron MP, Raffel LJ, Garchon HJ et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997; 6: 1275-1282.
9. Zhernakova A, Alizadeh BZ, Bevova M et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81:1284-1288.
10. Lowe CE, Cooper JD, Brusko T et al. Large-scale genetic fine mapping andgenotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39:1074-1082.
11. Liu S, Wang H, Jin Y et al. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet 2009; 18:358-365.
12. Moore F, Colli ML, Cnop M et al. PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis. Diabetes 2009; 58:1283-1291.
13. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41(6):703-707.
14. Knip M, Veijola R, Virtanen SM et al. Environmental triggers and determinants of type 1 diabetes. Diabetes 2005; 54 Suppl 2:S125-136.
15. Karvonen M, Viik-Kajander M, Moltchanova E et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23:1516-1526.
16. Kondrashova A, Reunanen A, Romanov A et al. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. Ann Med 2005; 37:67-72.
17. Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence-what can we learn from epidemiology? Pediatr Diabetes 2007; 8 (Suppl 6):6-14.
18. Delli AJ, Lindblad B, Carlsson A et al. Type 1 diabetes patients born to immigrants to Sweden increase their native diabetes risk and differ from Swedish patients in HLA types and islet autoantibodies. Pediatr Diabetes 2010; 11:513-520.
19. Akerblom HK, Vaarala O, Hyoty H et al. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002; 115:18-29.
20. EURODIAB. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia 2000;43:47-53.
21. Vaarala O. Environmental causes: dietary causes. Endocrinol Metab Clin North Am 2004; 33:17-26, vii.
22. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 2008; 1150:1-13.
23. Bottazzo GF, Dean BM, McNally JM et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353-360.
24. In't Veld P, Lievens D, De Grijse J et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 2007; 56:2400-2404.
25. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15:516-542.
26. Kim HS, Lee MS. Role of innate immunity in triggering and tuning of autoimmune diabetes. Curr Mol Med 2009; 9:30-44.
27. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008; 7:550-557.
28. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology and therapeutic strategies. Physiol Rev 91:79-118.
29. Rich SS, Akolkar B, Concannon P et al. Results of the MHC fine mapping workshop. Diabetes Obes Metab 2009; 11 (Suppl 1): 108-109.
30. Noble JA, Valdes AM, Cook M et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: Molecular analysis of 180 Caucasian, multiplex families. American Journal of Human Genetics 1996; 59:1134-1148.
31. Kockum I, Sanjeevi CB, Eastman S et al. Complex interaction between HLA DR and DQ in conferring risk for childhood type 1 diabetes. Eur J Immunogenet 1999; 26:361-372.
32. Graham J, Hagopian WA, Kockum I et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002; 51:1346-1355.
33. Fourlanos S, Varney MD, Tait BD et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008; 31:1546-1549.
34. Graham J, Kockum I, Sanjeevi CB et al. Negative association between type 1 diabetes and HLA DQB1∗0602- DQA1∗0102 is attenuated with age at onset. Swedish Childhood Diabetes Study Group. Eur J Immunogenet 1999; 26:117-127.
35. Moustakas AK, Papadopoulos GK. Molecular properties of HLA-DQ alleles conferring susceptibility to or protection from insulin-dependent diabetes mellitus: keys to the fate of islet beta-cells. Am J Med Genet 2002; 115:37-47.
36. Sadeharju K, Knip M, Hiltunen M et al. The HLA-DR phenotype modulates the humoral immune response to enterovirus antigens. Diabetologia 2003; 46:1100-1105.
37. Nejentsev S, Howson JM, Walker NM et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007; 450:887-892.
38. Gambelunghe G, Ghaderi M, Cosentino A et al. Association of MHC Class I chain-related A (MIC-A) gene polymorphism with Type I diabetes. Diabetologia 2000; 43:507-514.
39. Onengut-Gumuscu S, Ewens KG, Spielman RS et al. A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun 2004; 5:678-680.
40. Pugliese A, Zeller M, Fernandez A, Jr. et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997; 15:293-297.
41. Steck AK, Liu SY, McFann K et al. Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 2006; 7:274-278.
42. Hermann R, Lipponen K, Kiviniemi M et al. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin auto immunity and progression to type 1 diabetes. Diabetologia 2006; 49:1198-1208.
43. Grant SF, Qu HQ, Bradfield JP et al. Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes 2009; 58:290-295.
44. Cooper JD, Walker NM, Healy BC et al. Analysis of 55 autoimmune disease and type II diabetes loci: further confirmation of chromosomes 4q27, 12ql3.2 and 12q24.13 as type I diabetes loci and support for anew locus, 12ql3.3-ql4.1. Genes Immun 2009; 10 Suppl 1:S95-120.
45. Hakonarson H, Qu HQ, Bradfield JP et al. A novel susceptibility locus for type 1 diabetes on Chrl2ql3 identified by a genome-wide association study. Diabetes 2008; 57:1143-1146.
46. Hakonarson H, Grant SF, Bradfield JP et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007; 448:591-594.
47. Lehmann P, Sercarz E, Forsthuber T et al. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunology Today 1993; 14:203-208.
48. Reijonen H, Elliott JF, van Endert P et al. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T-cell epitopes among HLA-DRB1 ∗0401-positive individuals. J Immunol 1999; 163:1674-1681.
49. Nerup J, Andersen OO, Bendixen G et al. Anti-pancreatic, cellular hypersensitivity in diabetes mellitus. Experimental induction of anti-pancreatic, cellular hypersensitivity and associated morphological B-cell changes in the rat. Acta Allergol 1973; 28:231-249.
50. Eisenbarth GS, Jeffrey J. The natural history of type 1A diabetes. Arq Bras Endocrinol Metabol 2008; 52:146-155.
51. Dromey JA, Weenink SM, Peters GH et al. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T-cell determinants. J Immunol 2004; 172:4084-4090.
52. Endo T, Takizawa S, Tanaka S et al. Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. Diabetes 2009; 58:732-737.
53. Pupilli C, Giannini S, Marchetti P et al. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes 1999; 48:2309-2315.
54. Ozawa Y, Kasuga A, Nomaguchi H et al. Detection of autoantibodies to the pancreatic islet heat shock protein 60 in insulin-dependent diabetes mellitus. J Autoimmun 1999; 9:517-524.
55. Abulafia-Lapid R, Gillis D, Yosef O et al. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun 2003; 20:313-321.
56. Qin H, Mahon JL, Atkinson MA et al. Type 1 diabetes alters anti-hsp90 autoantibody isotype. J Autoimmun 2003; 20:237-245.
57. Martin S, Kardorf J, Schulte B et al. Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis. Diabetologia 1995; 38:351-355.
58. Jarchum I, Nichol L, Trucco M et al. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol 2008; 127:359-365.
59. Kasimiotis H, Fida S, Rowley MJ et al. Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. Autoimmunity 2001; 33:95-101.
60. Hawkes CJ, Wasmeier C, Christie MR et al. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996; 45:1187-1192.
61. Hirai H, Miura J, Hu Y et al. Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens. Clin Immunol 2008; 127:366-374.
62. Banga JP, Moore JK, Duhindan N et al. Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient. Clin Exp Immunol 2004; 135:74-84.
63. Weenink SM, Lo J, Stephenson CR et al. Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes. J Autoimmun 2009; 33:147-54.
64. Jaume JC, Parry SL, Madec AM et al. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B-lymphocytes on processing of T-cell determinants located within the antibody epitope. J Immunol 2002; 169:665-672.
65. Ziegler AG, Hummel M, Schenker M et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 999; 48:460-468.
66. Eisenbarth GS. Prediction of type 1 diabetes: the natural history of the prediabetic period. Adv Exp Med Biol 2004; 552:268-290.
67. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2:1279-1283.
68. Torn C, Mueller PW, Schlosser M et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51:846-852.
69. Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151-156.
70. Schranz DB, Lernmark A. Immunology in diabetes: an update. Diabetes Metab Rev 1998; 14:3-29.
71. Christie MR, Genovese S, Cassidy D et al. Antibodies to islet 37k antigen, butnotto glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994; 43:1254-1259.
72. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains ofthe smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993; 90:2832-2836.
73. Kobayashi T, Tanaka S, Okubo M et al. Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 2003; 88:4768-4775.
74. Reijonen H, Daniels TL, Lernmark A et al. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000; 49:1621-1626.
75. Oak S, Gilliam LK, Landin-Olsson M et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA 2008; 105:5471-5476.
76. Ortqvist E, Brooks-Worrell B, Lynch K et al. Changes in GAD65Ab-specific antiidiotypic antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity. J Clin Endocrinol Metab 1995:E310-318.
77. Palmer JP. Insulin autoantibodies: their role in the pathogenesis of IDDM. Diabetes Metab Rev 1987; 3:1005-1015.
78. Eisenbarth GS, Moriyama H, Robles DT et al. Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes. Autoimmun Rev 2002; 1:139-145.
79. Kukko M, Kimpimaki T, Korhonen S et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2005; 90:2712-2717.
80. Brooks-Worrell BM, Nielson D, Palmer JP. Insulin autoantibodies and insulin antibodies have similar binding characteristics. Proc Assoc Am Physicians 1999; 111:92-96.
81. Lan MS, Wasserfall C, Maclaren NK et al. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1996; 93:6367-6370.
82. Saeki K, Zhu M, Kubosaki A et al. Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes 2002; 51:1842-1850.
83. Zhang B, Lan MS, Notkins AL. Autoantibodies to IA-2 in IDDM: location of major antigenic determinants. Diabetes 1997; 46:40-43.
84. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104:17040-17045.
85. Vaziri-Sani F, Oak S, Radtke J et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 2010; 43:598-606.
86. Yu L, Rewers M, Gianani R et al. Anti islet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996; 81:4264-4267.
87. Knip M, Kukko M, Kulmala P et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 2002; 115:48-54.
88. Wasserfall CH, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 2006; 5:424-428.
89. Verge CF, Gianani R, Kawasaki E et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9:379-383.
90. Pinkse GG, Tysma OH, Bergen CA et al. Autoreactive CD8 T-cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102:18425-18430.
91. Roep BO, Atkinson MA, van Endert PM et al. Autoreactive T-cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T-cell assays. J Autoimmun 1999; 13:267-282.
92. Mallone R, Nepom GT. Targeting T-lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther 2005; 12:534-550.
93. Nagata M, Kotani R, Moriyama H et al. Detection of autoreactive T-cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T-cell workshop. Ann N Y Acad Sci 2004; 1037:10-15.
94. Mallone R, Nepom GT. MHC Class II tetramers and the pursuit of antigen-specific T-cells: define, deviate, delete. Clin Immunol 2004; 110:232-242.
95. Baker C, Petrich de Marquesini LG, Bishop AJ et al. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. J Clin Immunol 2008; 28:350-360.
96. Panina-Bordignon P, Lang R, van Endert PM et al. Cytotoxic T-cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995; 181:1923-1927.
97. Toma A, Laika T, Haddouk S et al. Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A∗0201 transgenic mice and in human type 1 diabetes. Diabetes 2009; 58:394-402.
98. Mannering SI, Pang SH, Williamson NA et al. The A-chain of insulin is a hot-spot for CD4+ T-cell epitopes in human type 1 diabetes. Clin Exp Immunol 2009; 156:226-231.
99. Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T-cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1-16.
100. Herold KC, Brooks-Worrell B, Palmer J et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58:2588-2595.
101. Oling V, Marttila J, Ilonen J et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005; 25:235-243.
102. Reijonen H, Novak EJ, Kochik S et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002; 51:1375-1382.
103. Arif S, Tree TI, Astill TP et al. Autoreactive T-cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-463.
104. Yang J, Danke N, Roti M et al. CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope. J Autoimmun 2008; 31:30-41.
105. Viglietta V, Kent SC, Orban T et al. GAD65-reactive T cells are activated in patients with autoimmune type la diabetes. J Clin Invest 2002; 109:895-903.
106. Danke NA, Yang J, Greenbaum C et al. Comparative study of GAD65-specific CD4+ T-cells in healthy and type 1 diabetic subjects. J Autoimmun 2005; 25:303-311.
107. Monti P, Scirpoli M, Rigamonti A et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007; 179:5785-5792.
108. Lindley S, Dayan CM, Bishop A et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-99.
109. Summers KL, Marleau AM, Mahon JL et al. Reduced IFN-alpha secretion by blood dendritic cells in human diabetes. Clin Immunol 2006; 121:81-89.
110. Vuckovic S, Withers G, Harris M et al. Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol 2007; 123:281-288.
111. Mollah ZU, Pai S, Moore C et al. Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol 2008; 180:3166-3175.
112. Meyers AJ, Shah RR, Gottlieb PA et al. Altered Toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med (Bed) 2010; 88:1221-1231.
113. Skarsvik S, Tiittanen M, Lindström A et al. Poor in vitro maturation and pro-inflammatory cytokine response of dendritic cells in children at genetic risk of type 1 diabetes. Scand J Immunol 2004; 60:647-652.
114. Allen JS, Pang K, Skowera A et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009; 58:138-145.
115. Nicoletti F, Conget I, Di Mauro M et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45:1107-1110.
116. Lampeter ER, Kishimoto TK, Rothlein R et al. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992; 41:1668-1671.
117. Rodacki M, Svoren B, Butty V et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007; 56:177-185.
118. Kis J, Engelmann P, Farkas K et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007; 81:654-662.
119. Chentoufi AA, Binder NR, Berka N et al. Advances in type I diabetes associated tolerance mechanisms. Scand J Immunol 2008; 68:1-11.
120. Venanzi ES, Benoist C, Mathis D. Good riddance: Thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 2004; 16:197-202.
121. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009; 27:287-312.
122. Diez J, Park Y, Zeller M et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001; 50:895-900.
123. Lieberman SM, Di Lorenzo TP. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 2003; 62:359-377.
124. Pugliese A, Brown D, Garza D et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001; 107:555-564.
125. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol 2007; 95:83-110.
126. Dustin ML. T-cell activation through immunological synapses andkinapses. Immunol Rev2008; 221:77-89.
127. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Annu Rev Immunol 1993; 11:191-212.
128. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-824.
129. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T-cell activation. J Exp Med 1996; 183:2541-2550.
130. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun 2000; 1:170-184.
131. Bour-Jordan H, Esensten JH, Martinez-Llordella M et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011; 241:180-205.
132. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007; 37 Suppl 1 :S53-60.
133. Tisch R, Wang B. Role of plasmacytoid dendritic cells in type 1 diabetes: friend or foe? Diabetes 2009; 58:12-13.
134. Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005;207:166-183.
135. Garcia CA, Prabakar KR, Diez J et al. Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, capture-independent fashion. J Immunol 2005; 175:2111-2122.
136. Wallet MA, Sen P, Tisch R. Immunoregulation of dendritic cells. Clin Med Res 2005; 3:166-175.
137. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108:1435-1440.
138. Yamazaki S, Inaba K, Tarbell KV et al. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T-cells including suppressors of alloreactivity. Immunol Rev 2006; 212:314-329.
139. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-774.
140. Sakaguchi S, Miyara M, Costantino CM et al. FOXP3+ regulatory T-cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
141. Tang Q, Bluestone JA. The Foxp3+ regulatory T-cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9:239-244.
142. Shevach EM. Fromvanillato 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25:195-201.
143. Roncarolo MG, Gregori S, Battaglia M et al. Interleukin-10-secreting type 1 regulatory T-cells in rodents and humans. Immunol Rev 2006; 212:28-50.
144. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
145. Tree TI, Roep BO, Peakman M. A mini meta-analysis of studies on CD4+CD25+ T-cells in human type 1 diabetes: report of the Immunology of Diabetes Society T-Cell Workshop. Ann N Y Acad Sci 2006; 1079:9-18.
146. Brusko T, Wasserfall C, McGrail K et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007; 56:604-612.
147. Roep BO, Kleijwegt FS, van Halteren AG et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010; 159:338-343.
148. Holm BC, Svensson J, Akesson C et al. Evidence for immunological priming and increased frequency of CD4+ CD25+ cord blood T-cells in children born to mothers with type 1 diabetes. Clin Exp Immunol 2006; 146:493-502.
149. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23:877-900.
150. Dufour FD, Silveira PA, Baxter AG. Interactions between B-lymphocytes and type 1 NKT cells in autoimmune diabetes. J Immunotoxicol 2008; 5:249-257.
151. Bauer S, Groh V, Wu J et al. Activation of NK cells and T-cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
152. Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131-140.
153. Lee PT, Putnam A, Benlagha K et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800.
154. Oikawa Y, Shimada A, Yamada S et al. High frequency of va24(+) vbetal 1(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25:1818-1823.
155. Rodacki M, Milech A, de Oliveira JE. NK cells and type 1 diabetes. Clin Dev Immunol 2006; 13:101-107.
156. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-89.
157. Lernmark A, Kloppel G, Stenger D et al. Heterogeneity of islet pathology in two infants with recent onset diabetes mellitus. Virchows Arch 1995; 425:631-640.
158. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37 Suppl 1:S34-45.
159. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5:219-226.
160. Lipman TH, Chang Y, Murphy KM. The epidemiology of type 1 diabetes in children in Philadelphia 1990-1994: evidence of an epidemic. Diabetes Care 2002; 25:1969-1975.
161. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes [see comments]. Lancet 1995; 346:221-223.
162. Mcintosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992; 340:414-415.
163. De Stefano F, Mullooly JP, Okoro CA et al. Childhood vaccinations, vaccination timing and risk of type 1 diabetes mellitus. Pediatrics 2001; 108:E112.
164. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920.
165. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003; 19:8-31.
166. van der Werf N, Kroese FG, Rozing J et al. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23:169-183.
167. Oikarinen S, Martiskainen M, Tauriainen S et al. Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 2011; 60:276-279.
168. Richardson SJ, Willcox A, Bone AJ et al. The prevalence of enteroviral capsid protein vp 1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009; 52:1143-1151.
169. Oikarinen M, Tauriainen S, Honkanen T et al. Detection of enteroviruses in the intestine of type 1 diabetic patients. Clin Exp Immunol 2008; 151:71-75.
170. Salminen K, Sadeharju K, Lonnrot M et al. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol 2003; 69:91-98.
171. Coppieters KT, von Herrath MG. Histopathology of type 1 diabetes: old paradigms and new insights. Rev Diabet Stud 2009; 6:85-96.
172. Blomqvist M, Juhela S, Erkkila S et al. Rotavirus infections and development of diabetes-associated autoantibodies during the first 2 years of life. Clin Exp Immunol 2002; 128:511-515.
173. Hultcrantz M, Huhn MH, Wolf M et al. Interferons induce an antiviral state in human pancreatic islet cells. Virology 2007; 367:92-101.
174. Cavallo MG, Baroni MG, Toto A et al. Viral infection induces cytokine release by beta islet cells. Immunology 1992; 75:664-668.
175. Oldstone MB. Molecular and cellular mechanisms, pathogenesis and treatment of insulin-dependent diabetes obtained through study of a transgenic model of molecular mimicry. Curr Top Microbiol Immunol 2005; 296:65-87.
176. Atkinson MA, Bowman MA, Campbell L et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94:2125-2129.
177. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med 1998; 4:231-239.
178. Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a beta-cell antigen. J Immunol 1993; 150:3080-3085.
179. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes 2008; 57:2863-2871.
180. Myers MA, Mackay IR, Rowley MJ et al. Dietary microbial toxins and type 1 diabetes-a new meaning for seed and soil. Diabetologia 2001; 44:1199-2000.
181. Virtanen SM, Jaakkola L, Rasanen L et al. Nitrate and nitrite intake and the risk for type 1 diabetes in Finnish children. Diabt. Med 1994; 11:656-662.
182. Dahlquist GG, Blom LG, Persson LA et al. Dietary factors and the risk of developing insulin dependent diabetes in childhood. BMJ 1990; 300:1302-1306.
183. Virtanen SM, Rasanen L, Aro A et al. Feeding in infancy and the risk of type 1 diabetes mellitus in Finnish children. The 'Childhood Diabetes in Finland' Study Group. Diabet Med 1992; 9:815-819.
184. Ziegler AG, Schmid S, Huber D et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003; 290:1721-1728.
185. Gerstein HC. Cow's milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care 1994; 17:13-19.
186. Martin JM, Trink B, Daneman D et al. Milk proteins in the etiology of insulin-dependent diabetes mellitus (IDDM). Ann Med 1991; 23:447-452.
187. Dahlquist G, Frisk G, Ivarsson SA et al. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia 1995; 38:1371-1373.
188. Fuchtenbusch M, Irnstetter A, Jager G et al. No evidence for an association of coxsackie virus infections during pregnancy and early childhood with development of islet autoantibodies in offspring of mothers or fathers with type 1 diabetes. J Autoimmun 2001; 17:333-340.
189. Stanley HM, Norris JM, Barriga K et al. Is presence of islet autoantibodies at birth associated with development of persistent islet autoimmunity? The Diabetes Autoimmunity Study in the Young (DAISY). Diabetes Care 2004; 27:497-502.
190. Elfving M, Lindberg B, Lynch K et al. Number of islet autoantibodies present in newly diagnosed type 1 diabetes children born to nondiabetic mothers is affected by islet autoantibodies present at birth. Pediatr Diabetes 2008;9:127-134.
191. Gutcher I, Becher B. APC-derived cytokines and T-cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119-1127.
192. Dong C. TH17 cells in development: an updated view oftheir molecular identity and genetic programming. Nat Rev Immunol 2008; 8:337-348.
193. Delon J, Germain RN. Information transfer at the immunological synapse. Curr Biol 2000; 10:R923-933.
194. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135.
195. Parker DC. T-cell-dependent B cell activation. Annu Rev Immunol 1993; 11:331-360.
196. Sutherland DER, Sibley RK, Xu X-Z et al. Twin-to twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Phys 1984; 97:80-87.
197. Uno S, Imagawa A, Okita K et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-α in patients with recent-onset type 1 diabetes. Diabetologia 2007; 50:596-601.
198. Willcox A, Richardson SJ, Bone AJ et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155:173-181.
199. Itoh N, Hanafusa T, Miyazaki A et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92:2313-2322.
200. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1034.
201. Dudda JC, Martin SF. Tissue targeting of T-cells by DCs and microenvironments. Trends Immunol 2004;25:417-421.
202. Hanninen A, Jalkanen S, Salmi M et al. Macrophages, T-cell receptor usage and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992; 90:1901-1910.
203. Greening JE, Tree TI, Kotowicz KT et al. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes 2003; 52:717-725.
204. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25:215-233.
205. Hogg N, Leitinger B. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J Leukoc Biol 2001; 69:893-898.
206. Nobile C, Lind M, Miro F et al. Cognate CD4+ T-cell-dendritic cell interactions induce migration of immature dendritic cells through dissolution of their podosomes. Blood 2008; 111:3579-3590.
207. Han B, Serra P, Yamanouchi J et al. Developmental control of CD8 T-cell-avidity maturation in autoimmune diabetes. J Clin Invest 2005; 115:1879-1887.
208. Dobersen MJ. Humoral autoimmunity in insulin-dependent (type I) diabetes mellitus. A current assessment. Surv Immunol Res 1982; 1329-338.
209. Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-1040.
210. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
211. Myers CD. Role of B cell antigen processing and presentation in the humoral immune response. FASEB J 1991; 5:2547-2553.
212. Wallberg M, Green EA. Are B cells a potential target for therapeutic intervention in the classical T-cell-mediated autoimmune disease type 1 diabetes? Inflamm Allergy Drug Targets 2009; 8:130-138.
213. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44:2115-2133.
214. Eizirik DL, Kutlu B, Rasschaert J et al. Use of microarray analysis to unveil transcription factor and gene networks contributing to Beta cell dysfunction and apoptosis. Ann N Y Acad Sci 2003; 1005:55-74.
215. Bendtzen K, Mandrup-Poulsen T, Nerup J et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232:1545-1547.
216. Arnush M, Heitmeier MR, Scarim AL et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102:516-526.
217. Thomas HE, Darwiche R, Corbett JA et al. Interleukin-1 plus γ-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 2002; 51:311-316.
218. Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005; 12:580-591.
219. Moriwaki M, Itoh N, Miyagawa J et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 1999; 42:1332-1340.
220. Skowera A, Ellis RJ, Varela-Calvino R et al. CTLs are targetedto kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
221. Planas R, Pujol-Borrell R, Vives-Pi M. Global gene expression changes in type 1 diabetes: insights into autoimmune response in the target organ and in the periphery. Immunol Lett 2010; 133:-61.